See more : Agricultural Bank of China Limited (1288.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Catheter Precision, Inc. (VTAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catheter Precision, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Axactor ASA (ACR.OL) Income Statement Analysis – Financial Results
- Farmhouse, Inc (FMHS) Income Statement Analysis – Financial Results
- Enbridge Inc. (ENB-PFA.TO) Income Statement Analysis – Financial Results
- Select Bancorp, Inc. (SLCT) Income Statement Analysis – Financial Results
- Gruma, S.A.B. de C.V. (GPAGF) Income Statement Analysis – Financial Results
Catheter Precision, Inc. (VTAK)
About Catheter Precision, Inc.
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 442.00K | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 30.00K | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | 412.00K | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | 93.21% | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 475.00K | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 0.00 | 2.23M | 0.00 | 25.97M | 51.55M | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 60.93M | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 14.95M | 5.32M |
| Operating Expenses | 78.53M | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 78.56M | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 347.00K | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 2.08M | 421.00K | 1.40M | 2.00M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -15.11M | -22.37M | -27.70M | -33.30M | -54.94M | -30.18M | -17.54M | -4.10M |
| EBITDA Ratio | -3,418.55% | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -78.12M | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -17,673.98% | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 7.55M | -4.07M | 2.01M | 88.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -70.57M | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -15,966.52% | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 0.00 | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -70.57M | -26.87M | -25.07M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -15,966.52% | -191,892.86% | -113,954.55% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Catheter Precision's VIVO is Now Eligible for National Reimbursement in the UK
Catheter Precision Showcasing its Innovative 3D Mapping System
Catheter Precision, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Catheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q
Source: https://incomestatements.info
Category: Stock Reports